English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/20212
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis

AuthorsSanmartí, Raimon; Graell, Eduard; Pérez Rodríguez, María L.; Ercilla, Guadalupe; Viñas, Odette; Gómez-Puerta, José A.; Gratacós, Jordi; Balsa, Alejandro; Gómara Elena, María José; Larrosa, Marta; Cañete, Juan D.; Haro Villar, Isabel
Issue DateSep-2009
PublisherBioMed Central
CitationArthritis Research and Therapy 11(R135): (2009)
AbstractIntroduction Evidence suggests that citrullinated fibrin(ogen) may be a potential in vivo target of anticitrullinated protein/ peptide antibodies (ACPA) in rheumatoid arthritis (RA). We compared the diagnostic yield of three enzyme-linked immunosorbent assay (ELISA) tests by using chimeric fibrin/ filaggrin citrullinated synthetic peptides (CFFCP1, CFFCP2, CFFCP3) with a commercial CCP2-based test in RA and analyzed their prognostic values in early RA.
Methods Samples from 307 blood donors and patients with RA (322), psoriatic arthritis (133), systemic lupus erythematosus (119), and hepatitis C infection (84) were assayed by using CFFCP- and CCP2-based tests. Autoantibodies also were analyzed at baseline and during a 2-year follow-up in 98 early RA patients to determine their prognostic value.
Results With cutoffs giving 98% specificity for RA versus blood donors, the sensitivity was 72.1% for CFFCP1, 78.0% for CFFCP2, 71.4% for CFFCP3, and 73.9% for CCP2, with positive predictive values greater than 97% in all cases. CFFCP sensitivity in RA increased to 80.4% without losing specificity when positivity was considered as any positive anti-CFFCP status. Specificity of the three CFFCP tests versus other rheumatic populations was high (> 90%) and similar to those for the CCP2. In early RA, CFFCP1 best identified patients with a poor radiographic outcome. Radiographic progression was faster in the small subgroup of CCP2-negative and CFFCP1- positive patients than in those negative for both autoantibodies. CFFCP antibodies decreased after 1 year, but without any correlation with changes in disease activity.
Conclusions CFFCP-based assays are highly sensitive and specific for RA. Early RA patients with anti-CFFCP1 antibodies, including CCP2-negative patients, show greater radiographic progression.
Description9 pages, 3 figures, 2 tables.
Publisher version (URL)http://dx.doi.org/10.1186/ar2802
URIhttp://hdl.handle.net/10261/20212
DOI10.1186/ar2802
ISSN1478-6354
Appears in Collections:(IQAC) Artículos
Files in This Item:
File Description SizeFormat 
ar2802.pdf642,34 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.